SPINK1 has been considered a tumor-associated trypsin inhibitor, and overexpression of SPINK1 is a predictor of unfavorable outcomes in ovarian [14], prostate [15], liver [16], breast [17], and colon [18] cancers. This evidence concerns the gene SPINK1 and neoplasm.